MASH CALL Initiative for Fast and Reliable Identification and Comparison of Clinical Candidates

Select and compare the best anti-steatotic and anti-fibrotic drug candidates and follow-up with a comprehensive phenotypic analysis

MASH (Metabolic Dysfunction-associated Steatohepatitis, renamed from NASH) is a complex, multi-faceted disease, and the InSphero models are designed to reflect this complexity. Our models empower you to simultaneously assess multiple disease parameters, including steatosis, inflammation, and fibrosis. Consequently, you and your team gain a more comprehensive understanding of your asset’s impact and efficacy.

Join our MASH CALL Initiative and leverage our pioneering approach for drug discovery with valuable insights about the:

Anti-steatotic and anti-fibrotic effects of your compounds
Comparison with clinical candidates and reference controls

Why MASH Screening with InSphero?

We inspire researchers, worldwide, to reach their full potential so that life changing therapies can ultimately make it into the hands of patients.

Fast and translational MASH phenotypic candidate selection process

Screening of MASH candidates for anti-steatotic, anti-fibrotic efficacy and safety assessment simultaneously

Most cost-effective human pre-clinical model

Improvements of scalability and automation have lead to a significant optimization of cost

Benchmarking with clinical candidates

Direct comparison with existing clinical candidates in the MASH space

Leading to a comprehensive phenotypic analysis follow-up

MASH Screening is only the beginning of the journey to identify successful candidates with extended readouts

Your Success is Our Mission

Schedule a consultation with our experts

MASH Call Process

Compound Submission

Submit your candidates from small molecules, antibodies, peptides to siRNA/ASOs.

Treatment in 3D InSight™ MASH model for efficacy analysis

7 concentration dose range treatment of submitted compounds with positive controls and clinical candidates for phenotypic analysis

Endpoint analysis

Extracellular LDH, intracellular triglycerides and secreted pro-collagen 1 as surrogate markers of toxicology, steatosis and fibrosis respectively

Data analysis

Selection of candidates and comparison to anti-fibrotic and anti-steatotic scores with pre-clinical and clinical candidates

Why our customers joined the MASH CALL Initiative

“For our lead target at Inipharm, a human-centric system is extremely important for proof of concept. InSphero’s primary human liver spheroids under culture conditions that resulted in fibrotic and inflammatory processes was able to reproduce known human genetic phenotypes relating to our target of interest. Additionally, the MASH CALL testing platform was an efficient way for us to assess multiple leads for potential efficacy.”

Dr. Heather Hsu, CSO Inipharm

Latest from the Blog: The MASH CALL Initiative

The MASH Screening Program: A Strategic Pathway for Screening and Selecting Drug Candidates to Assemble IND Packages for Regulatory Approval

One of the challenges in drug discovery is to reduce drug attrition rates by identifying the best candidates early on. There is a need for advanced in vitro 3D models that predict future clinical responses reliably. These models need to be scalable at a low cost, automation-compatible, and able to provide a wide variety of readouts for complex phenotypic analysis. Having this in mind, we wanted to tackle the next avenue of drug discovery for MASH by offering solutions from screening of candidates to advanced phenotypic characterization. We initiated a MASH CALL campaign offering drug testing screening at 3 announced fixed dates spread over the calendar year.

Featured resources

Publication

Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model

Publication

A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

Webinar

MASH CALL Initiative for Fast and Reliable Identification and Comparison of Clinical Candidates

Select and compare the best anti-steatotic and anti-fibrotic drug candidates and follow-up with a comprehensive phenotypic analysis